KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 120.61%.

  • Aquestive Therapeutics' EBITDA Margin fell 356200.0% to 120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.32%, marking a year-over-year increase of 5840700.0%. This contributed to the annual value of 4378.67% for FY2024, which is 43631100.0% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported EBITDA Margin of 120.61% as of Q3 2025, which was down 356200.0% from 135.44% recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year EBITDA Margin high stood at 72.46% for Q1 2023, and its period low was 618.35% during Q2 2021.
  • For the 5-year period, Aquestive Therapeutics' EBITDA Margin averaged around 128.6%, with its median value being 109.36% (2022).
  • As far as peak fluctuations go, Aquestive Therapeutics' EBITDA Margin surged by 4145800bps in 2022, and later crashed by -1788900bps in 2024.
  • Over the past 5 years, Aquestive Therapeutics' EBITDA Margin (Quarter) stood at 261.28% in 2021, then surged by 56bps to 115.63% in 2022, then surged by 47bps to 61.42% in 2023, then skyrocketed by 162bps to 38.17% in 2024, then crashed by -416bps to 120.61% in 2025.
  • Its EBITDA Margin was 120.61% in Q3 2025, compared to 135.44% in Q2 2025 and 262.96% in Q1 2025.